-
公开(公告)号：WO2006049983A2
公开(公告)日：2006-05-11
申请号：PCT/US2005/038531
申请日：2005-10-27
Applicant: BIOREXIS PHARMACEUTICAL CORPORATION , PRIOR, Christopher, P. , SADEGHI, Homayoun , BALLANCE, David, J. , TURNER, Andrew
Inventor： PRIOR, Christopher, P. , SADEGHI, Homayoun , BALLANCE, David, J. , TURNER, Andrew
CPC classification number: C07K14/575 , C07K2319/01
Abstract: Modified fusion proteins of transferring and therapeutic proteins or peptides including, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Abstract translation: 公开了转移和治疗性蛋白质或肽的修饰融合蛋白，包括具有增加的血清半衰期或血清稳定性的融合蛋白。 优选的融合蛋白包括经修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化，结合铁和/或结合转铁蛋白受体。
-
公开(公告)号：WO2004020405A3
公开(公告)日：2005-09-01
申请号：PCT/US0326818
申请日：2003-08-28
Applicant: BIOREXIS PHARMACEUTICAL CORP , PRIOR CHRISTOPHER P , LAI CHAR-HUEI , SADEGHI HOMAYOUN , TURNER ANDREW J
Inventor： PRIOR CHRISTOPHER P , LAI CHAR-HUEI , SADEGHI HOMAYOUN , TURNER ANDREW J
IPC: A61K38/00 , A61K47/48 , C07K7/06 , C07K7/08 , C07K14/705 , C07K14/79 , A61K38/40 , A61K38/16 , A61K38/41
CPC classification number: C07K14/79 , A01K2217/05 , A61K38/00 , A61K47/644 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/47 , C07K14/565 , C07K2319/00 , C07K2319/035 , C12N2740/16122
Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Abstract translation: 公开了转运蛋白和治疗性蛋白质的修饰融合蛋白或包括可溶性毒素受体的肽，具有增加的血清半衰期或血清稳定性。 优选的融合蛋白包括经修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化，结合铁和/或结合转铁蛋白受体。
-
公开(公告)号：WO2004020588A3
公开(公告)日：2005-04-21
申请号：PCT/US0326779
申请日：2003-08-28
Applicant: BIOREXIS PHARMACEUTICAL CORP , PRIOR CHRISTOPHER P , TURNER ANDREW J , SADEGHI HOMAYOUN
Inventor： PRIOR CHRISTOPHER P , TURNER ANDREW J , SADEGHI HOMAYOUN
CPC classification number: C12N15/1037 , C07K2319/31 , C07K2319/75 , C12N15/1044 , C12N15/62
Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Abstract translation: 公开了具有增加的血清半衰期或血清稳定性的转铁蛋白和治疗性蛋白质或肽的修饰融合蛋白。 优选的融合蛋白包括经修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化，结合铁和/或结合转铁蛋白受体。
-
公开(公告)号：WO2004020404A2
公开(公告)日：2004-03-11
申请号：PCT/US0326744
申请日：2003-08-28
Applicant: BIOREXIS PHARMACEUTICAL CORP , SADEGHI HOMAYOUN , PRIOR CHRISTOPHER P , TURNER ANDREW
Inventor： SADEGHI HOMAYOUN , PRIOR CHRISTOPHER P , TURNER ANDREW
IPC: A01K67/00 , A61K38/00 , A61K39/395 , A61K47/48 , C07D20060101 , C07H21/04 , C07K14/79 , C07K16/00 , C07K16/24 , C07K19/00 , C12N15/12 , C12N15/13 , C12N15/62 , C12N15/63 , C12N15/65 , C12N15/86 , C07D
CPC classification number: C12N15/62 , A01K2217/05 , A61K38/00 , A61K47/644 , C07K14/79 , C07K16/241 , C07K2318/20 , C07K2319/00 , C07K2319/035
Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Abstract translation: 公开了具有增加的血清半衰期或血清稳定性的转铁蛋白和治疗性蛋白或肽的修饰融合蛋白，优选抗体可变区。 优选的融合蛋白包括那些经过修饰的蛋白，使得转铁蛋白部分不显示或减少糖基化，与铁结合和/或与转铁蛋白受体结合。
-
公开(公告)号：WO1995025789A1
公开(公告)日：1995-09-28
申请号：PCT/US1995003668
申请日：1995-03-22
Applicant: THE IMMUNE RESPONSE CORPORATION , HRINDA, Michael, E. , PRIOR, Christopher, P. , MITSCHELEN, Jonathan, J. , IRISH, Thomas, W. , WEBER, David, M. , GORE, Richard, S. , HARTER, James, J. , BAY, Pierre, M. , TARR, George, C.
Inventor： THE IMMUNE RESPONSE CORPORATION
IPC: C12N07/02
CPC classification number: C12N7/00 , C07K14/005 , C12N2740/16022 , C12N2740/16051 , C12N2740/16122
Abstract: This invention is directed to a continuous process for producing viral particles comprising providing in a perfused growth medium a population of viable virally infected non-lytic cells, and removing medium containing said cells at a rate to maintain the steady-state log-phase growth of cells remaining in said perfused growth medium. The invention is also directed to a process for purifying retroviral particles comprising passing a solution comprising the retroviral particles and contaminants through an anion exchange resin, and eluting the retroviral particles from the resin.
Abstract translation: 本发明涉及用于生产病毒颗粒的连续方法，其包括在灌注的生长培养基中提供存活的病毒感染的非溶解细胞群，以及以保持稳态对数期生长的速率除去含有所述细胞的培养基 剩余在所述灌注生长培养基中的细胞。 本发明还涉及用于纯化逆转录病毒颗粒的方法，包括使包含逆转录病毒颗粒和污染物的溶液通过阴离子交换树脂，并从树脂中洗脱逆转录病毒颗粒。
-
Patent Agency Ranking
公开(公告)号：WO2007047504A3
公开(公告)日：2007-04-26
申请号：PCT/US2006/040207
申请日：2006-10-16
Applicant: BIOREXIS PHARMACEUTICAL CORPORATION , SADEGHI, Homayoun , TURNER, Andrew, J. , PRIOR, Christopher, P. , BALLANCE, David, J.
Inventor： SADEGHI, Homayoun , TURNER, Andrew, J. , PRIOR, Christopher, P. , BALLANCE, David, J.
IPC: A61K38/00
Abstract: Fusion proteins of transferrin and natriuretic peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
-
7.发明申请NATRIURETIC PEPTIDE MODIFIED TRANSFERRIN FUSION PROTEINS 审中-公开NATRIURETIC PEPTIDE MODIFY TRANSFERRIN FUSION PROTEINS
公开(公告)号：WO2007047504A2
公开(公告)日：2007-04-26
申请号：PCT/US2006040207
申请日：2006-10-16
Applicant: BIOREXIS PHARMACEUTICAL CORP , SADEGHI HOMAYOUN , TURNER ANDREW J , PRIOR CHRISTOPHER P , BALLANCE DAVID J
Inventor： SADEGHI HOMAYOUN , TURNER ANDREW J , PRIOR CHRISTOPHER P , BALLANCE DAVID J
IPC: A61K38/40
CPC classification number: C07K14/79 , A61K38/00 , A61K47/644 , C07K14/58 , C07K2319/31
Abstract: Fusion proteins of transferrin and natriuretic peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Abstract translation: 公开了具有增加的血清半衰期或血清稳定性的转铁蛋白和利尿钠肽的融合蛋白。 优选的融合蛋白包括经修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化，结合铁和/或结合转铁蛋白受体。
-
公开(公告)号：WO2006096515A2
公开(公告)日：2006-09-14
申请号：PCT/US2006/007617
申请日：2006-03-06
Applicant: BIOREXIS PHARMACEUTICAL CORPORATION , SADEGHI, Homayoun , TURNER, Andrew J. , PRIOR, Christopher P. , BALLANCE, David J.
Inventor： SADEGHI, Homayoun , TURNER, Andrew J. , PRIOR, Christopher P. , BALLANCE, David J.
IPC: C07K14/605 , C07H21/04 , C12P21/04 , A61K38/26 , A61K38/40
CPC classification number: C07K14/605 , A61K38/26 , A61K47/644 , C07K14/79 , C07K2319/00
Abstract: Modified fusion proteins of a transferrin moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment of Type 2 diabetes, Type 1 diabetes, obesity, congestive heart failure, and non-fatty liver disease.
Abstract translation: 公开了具有增加的生产力，生物活性和血清半衰期的转铁蛋白部分，GLP-1部分和接头部分的修饰融合蛋白。 优选的融合蛋白包括修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化。 本发明的融合蛋白可用于治疗2型糖尿病，1型糖尿病，肥胖症，充血性心力衰竭和非脂肪性肝病。
-
公开(公告)号：WO2004019872A3
公开(公告)日：2004-05-21
申请号：PCT/US0326778
申请日：2003-08-28
Applicant: BIOREXIS PHARMACEUTICAL CORP , PRIOR CHRISTOPHER P , SADEGHI HOMAYOUN , TURNER ANDREW
Inventor： PRIOR CHRISTOPHER P , SADEGHI HOMAYOUN , TURNER ANDREW
IPC: C07K14/705 , C07K14/79 , C12N5/02 , C12P21/04 , C01K1/00 , C07H21/04 , C12N5/00 , C12N15/00 , C12N15/09 , C12N15/63 , C12N15/70 , C12N15/74 , C12P21/00 , C01K14/00
CPC classification number: C07K14/70582 , C07K14/79 , C07K2319/035
Abstract: Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally.
Abstract translation: 公开了含有转铁蛋白和治疗性蛋白质的修饰的融合蛋白或具有增加的血清半衰期或增加的血清稳定性的肽的药物组合物。 优选的融合蛋白包括经修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化，但确实表现出与铁和/或转铁蛋白受体的结合。 这样的融合蛋白可以口服给药。
-
公开(公告)号：WO2004020588A2
公开(公告)日：2004-03-11
申请号：PCT/US2003/026779
申请日：2003-08-28
Applicant: BIOREXIS PHARMACEUTICAL CORPORATION , PRIOR, Christopher, P. , TURNER, Andrew, J. , SADEGHI, Homayoun
Inventor： PRIOR, Christopher, P. , TURNER, Andrew, J. , SADEGHI, Homayoun
IPC: C12N
CPC classification number: C12N15/1037 , C07K2319/31 , C07K2319/75 , C12N15/1044 , C12N15/62
Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Abstract translation: 公开了具有增加的血清半衰期或血清稳定性的转铁蛋白和治疗性蛋白质或肽的修饰融合蛋白。 优选的融合蛋白包括经修饰的融合蛋白，使得转铁蛋白部分不显示或降低糖基化，结合铁和/或结合转铁蛋白受体。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.021 seconds)
